Skip to main content

Recent News & Research

OncLive
ResearchTreatments

Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results

*November 2023* Although biomarker testing is crucial for determining optimal targeted therapies for patients with advanced non–small cell lung cancer (NSCLC), the time between conducting these tests and receiving results poses challenges for both oncologists and patients, according to Stephen V. Liu, MD. “There are cases where we need to…
laurabbook@gmail.com
December 27, 2023
OncLive
ResearchTreatments

Discussing Biomarkers and Best Options in NSCLC

*November 2023* In this video, Hossein Borghaei, MS, DO, chief of Thoracic Medical Oncology, professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic malignancies, provides an overview on his presentation given at the 18th Annual New York Lung Cancers Symposium®.…
laurabbook@gmail.com
December 27, 2023
Targeted Oncology
ResearchTreatments

Frontline Combinations Better Survival Rates in EGFRm Lung Cancer

*November 2023* First-line combination treatment regimens are improving progression-free survival (PFS) rates in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to Julia Rotow, MD.1 Prior to November 2023, the main first-line therapy utilized for the treatment of patients with EGFR-mutated lung cancer was osimertinib (Tagrisso) monotherapy, based on the phase…
laurabbook@gmail.com
December 27, 2023
ResearchStories

Clinician Spotlight: Dr. Elaine Shum

*December 2023* This month we have the honor of featuring Dr. Elaine Shum, who is Assistant Professor of Medicine at NYU Perlmutter Cancer Center in New York.  Dr. Shum participated in the 2021 EGFR Resisters Research Summit and received the Distinguished Young Investigator Research Award for her study Lung Cancer Screening…
laurabbook@gmail.com
December 27, 2023